PTGX (STOCKS)
Protagonist Therapeutics, Inc
$151.420000
-0.590000 (-0.39%)
Prev close: $152.010000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Dinesh V. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $11,266.24M
- Employees
- 130
- P/E (TTM)
- 146.57
- P/B (TTM)
- 11.68
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$2.29 | $2.12 | +0.1662 | +7.83% |
|
Mar 2026 (Q1)
|
$0.05 | $-0.54 | +0.5935 | +109.20% |
|
Dec 2025 (Q4)
|
$-0.69 | $-0.50 | -0.1917 | -38.47% |
|
Sep 2025 (Q3)
|
$-0.62 | $-0.65 | +0.0318 | +4.88% |
Financial Statements
| Revenues | $281.99M |
| Benefits Costs and Expenses | $197.65M |
| Costs And Expenses | $197.65M |
| Operating Expenses | $223.65M |
| Research and Development | $175.16M |
| Other Operating Expenses | $48.49M |
| Operating Income/Loss | $58.34M |
| Income/Loss From Continuing Operations After Tax | $82.91M |
| Income/Loss From Continuing Operations Before Tax | $84.34M |
| Income Tax Expense/Benefit | $1.43M |
| Net Income/Loss | $82.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $82.91M |
| Net Income/Loss Available To Common Stockholders, Basic | $82.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.21 |
| Diluted Earnings Per Share | $1.02 |
| Basic Average Shares | 194,950,474 |
| Diluted Average Shares | 205,426,487 |
| Assets | $885.54M |
| Current Assets | $807.15M |
| Noncurrent Assets | $78.40M |
| Fixed Assets | $3.46M |
| Other Non-current Assets | $74.94M |
| Liabilities | $44.00M |
| Current Liabilities | $37.18M |
| Accounts Payable | $3.46M |
| Other Current Liabilities | $33.72M |
| Noncurrent Liabilities | $6.82M |
| Equity | $841.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $841.54M |
| Liabilities And Equity | $885.54M |
| Net Cash Flow From Operating Activities | $131.20M |
| Net Cash Flow From Operating Activities, Continuing | $131.20M |
| Net Cash Flow From Investing Activities | $78.72M |
| Net Cash Flow From Investing Activities, Continuing | $78.72M |
| Net Cash Flow From Financing Activities | $41.61M |
| Net Cash Flow From Financing Activities, Continuing | $41.61M |
| Net Cash Flow | $251.53M |
| Net Cash Flow, Continuing | $251.53M |
| Comprehensive Income/Loss | $82.10M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $82.10M |
| Other Comprehensive Income/Loss | -$40.15M |
| Other Comprehensive Income/Loss Attributable To Parent | -$813.00K |